Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population
We sought to disentangle the effects of statins and other lipid-lowering drugs and the underlying dyslipidemia for which they are prescribed on breast cancer risk.
We conducted a case–control study within the linked Surveillance, Epidemiology, and End results (SEER)-Medicare data. Cases were women with invasive breast cancer aged 66 + years (N = 30,004) identified by SEER registries (years 2007–2011). Controls were women (N = 198,969) identified from a 5% random sample of Medicare recipients alive and breast cancer free in year of selection. Participants had a minimum of 13 months of Part A, Part B non-health maintenance organization Medicare and Part D Medicare coverage at least 13 months preceding cancer diagnosis/selection. Exposures were assessed until 12 months before diagnosis/control selection. Odds ratios (OR) and 99.9% confidence intervals (CI) were estimated using adjusted unconditional and multinomial logistic regression.
ORs of invasive breast cancer associated with dyslipidemia, statins, and non-statin lipid-lowering drugs were 0.86 (99.9% CI 0.81–0.90), 1.07 (99.9% CI 1.03–1.13) and 1.03 (99.9% CI 0.95–1.11), respectively. Risk reductions with dyslipidemia were slightly greater when untreated than treated and did not vary much by time between dyslipidemia and breast cancer diagnosis. Whether treated or untreated, dyslipidemia was associated with greater reductions in risk for later stage than earlier stage breast cancer (p-heterogeneity < 0.0001).
Lipid-lowering drugs did not account for the lower breast cancer risk associated with dyslipidemia. Our data do not support using statins or other lipid-lowering drugs to prevent breast cancer.
KeywordsBreast cancer Dyslipidemia Statins Lipid-lowering drugs
We would like to acknowledge the programming support of Winnie Ricker at Information Management Services, Inc.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Study complies with the current laws of the United States, the country within which it was performed.
- 5.Desai P, Lehman A, Chlebowski RT, Kwan ML, Arun M, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE, LeBoff M, Cauley J, Cote M, Beebe-Dimmer J, Jay A, Simon MS (2015) Statins and breast cancer stage and mortality in the Women’s Health Initiative. Cancer Causes Control 26:529–539CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjørge T, Borena W, Hӓggstrӧm C, Engeland A, Nagel G, Almquist M, Selmer R, Tretli S, Concin H, Hallmans G, Jonsson H, Stattin P, Ulmer H (2013) Total serum cholesterol and cancer incidence in the Metabolic Syndrome and Cancer Project (Me-Can). PLoS ONE 8(1):e54242. https://doi.org/10.1371/journal.pone.0054242 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Expert Panel of Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486–2497CrossRefGoogle Scholar